ETF Holdings Breakdown of QGEN

QGEN institutional holdings

The adjusted close for QGEN on 2025-11-11 was 44.22

The following institutional investment holdings of QGEN have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-11	IE0002EKOXU6 (iShares Russell 1000 Value UCITS ETF)	1,719	USD 76,014	44.22
2025-11-11	IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc))	4	USD 177 2.3%	44.25
Total =		1,723	USD 76,191

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with QGEN

QIAGEN N.V. (NYSE:QGEN) Receives $49.69 Consensus Target Price from Analysts

QIAGEN N.V. (NYSE:QGEN – Get Free Report) has received a consensus rating of “Hold” from the eleven brokerages that are covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month price target among analysts that […] - 2025-09-19 02:43:08

William Blair Forecasts QIAGEN’s Q2 Earnings (NYSE:QGEN)

QIAGEN N.V. (NYSE:QGEN – Free Report) – Analysts at William Blair dropped their Q2 2026 earnings per share estimates for QIAGEN in a research note issued to investors on Thursday, August 7th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of $0.62 per share for the quarter, down from their […] - 2025-08-12 05:26:53

Federated Hermes Inc. Takes Position in Qiagen N.V. (NYSE:QGEN)

Federated Hermes Inc. acquired a new stake in Qiagen N.V. (NYSE:QGEN – Free Report) in the first quarter, HoldingsChannel.com reports. The fund acquired 3,739 shares of the company’s stock, valued at approximately $150,000. A number of other hedge funds also recently made changes to their positions in QGEN. LPL Financial LLC lifted its position in […] - 2025-08-11 04:48:50

Qiagen (NYSE:QGEN) Cut to Buy at Wall Street Zen

Qiagen (NYSE:QGEN – Get Free Report) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a report issued on Monday. A number of other research firms also recently weighed in on QGEN. Robert W. Baird raised their target price on shares of Qiagen from $42.00 to […] - 2025-08-11 02:22:52

Qiagen (NYSE:QGEN) Stock Rating Upgraded by Wall Street Zen

Qiagen (NYSE:QGEN – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research note issued on Sunday. Other research analysts also recently issued reports about the company. Robert W. Baird upped their price objective on Qiagen from $42.00 to $43.00 and gave […] - 2025-08-05 02:43:13

New York State Common Retirement Fund Acquires 3,623 Shares of QIAGEN N.V. (NYSE:QGEN)

New York State Common Retirement Fund raised its holdings in QIAGEN N.V. (NYSE:QGEN – Free Report) by 3.0% in the first quarter, HoldingsChannel.com reports. The firm owned 125,126 shares of the company’s stock after purchasing an additional 3,623 shares during the quarter. New York State Common Retirement Fund’s holdings in QIAGEN were worth $5,024,000 as […] - 2025-07-22 07:09:12

Signaturefd LLC Sells 10,326 Shares of Qiagen N.V. (NYSE:QGEN)

Signaturefd LLC reduced its position in shares of Qiagen N.V. (NYSE:QGEN – Free Report) by 75.5% in the first quarter, Holdings Channel reports. The firm owned 3,354 shares of the company’s stock after selling 10,326 shares during the period. Signaturefd LLC’s holdings in Qiagen were worth $135,000 at the end of the most recent reporting […] - 2025-07-21 05:09:43

Bank of New York Mellon Corp Sells 41,846 Shares of Qiagen N.V. (NYSE:QGEN)

Bank of New York Mellon Corp cut its holdings in Qiagen N.V. (NYSE:QGEN – Free Report) by 4.5% in the 1st quarter, Holdings Channel reports. The institutional investor owned 882,919 shares of the company’s stock after selling 41,846 shares during the period. Bank of New York Mellon Corp’s holdings in Qiagen were worth $35,449,000 as […] - 2025-07-15 05:08:56

Qiagen N.V. (NYSE:QGEN) Receives Consensus Rating of “Hold” from Analysts

Qiagen N.V. (NYSE:QGEN – Get Free Report) has received a consensus rating of “Hold” from the ten brokerages that are presently covering the stock, Marketbeat.com reports. Seven investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokerages […] - 2025-07-03 02:56:48

Illinois Municipal Retirement Fund Sells 1,787 Shares of Qiagen N.V. (NYSE:QGEN)

Illinois Municipal Retirement Fund cut its holdings in shares of Qiagen N.V. (NYSE:QGEN – Free Report) by 2.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,531 shares of the company’s stock after selling 1,787 shares during the quarter. […] - 2025-06-30 05:14:52

Qiagen (NYSE:QGEN) Earns Overweight Rating from Analysts at Barclays

Stock analysts at Barclays began coverage on shares of Qiagen (NYSE:QGEN – Get Free Report) in a research note issued on Tuesday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $55.00 price target on the stock. Barclays‘s price objective would indicate a potential upside of 15.84% from the stock’s current price. A […] - 2025-06-26 02:48:52

Blue Trust Inc. Acquires 3,157 Shares of QIAGEN N.V. (NYSE:QGEN)

Blue Trust Inc. grew its holdings in QIAGEN N.V. (NYSE:QGEN – Free Report) by 30.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,519 shares of the company’s stock after acquiring an additional 3,157 shares during the period. Blue Trust Inc.’s holdings in […] - 2025-06-22 05:22:57

Qiagen (NYSE:QGEN) Shares Sold by Rhumbline Advisers

Rhumbline Advisers decreased its stake in Qiagen (NYSE:QGEN – Free Report) by 5.4% during the 1st quarter, HoldingsChannel reports. The firm owned 194,303 shares of the company’s stock after selling 11,088 shares during the period. Rhumbline Advisers’ holdings in Qiagen were worth $7,801,000 as of its most recent filing with the Securities and Exchange Commission. […] - 2025-06-11 05:54:44

Brokerages Set Qiagen (NYSE:QGEN) Target Price at $48.42

Qiagen (NYSE:QGEN – Get Free Report) has earned an average recommendation of “Hold” from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokerages […] - 2025-06-11 02:22:44

Tidal Investments LLC Buys 7,815 Shares of Qiagen (NYSE:QGEN)

Tidal Investments LLC grew its stake in Qiagen (NYSE:QGEN – Free Report) by 72.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,559 shares of the company’s stock after acquiring an additional 7,815 shares during the period. Tidal Investments […] - 2025-05-27 05:21:01

Qiagen (NYSE:QGEN) Holdings Lifted by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC boosted its holdings in Qiagen (NYSE:QGEN – Free Report) by 770.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,490 shares of the company’s stock after acquiring an additional 2,204 shares during the quarter. Tower […] - 2025-05-09 05:55:01

Qiagen (NYSE:QGEN) Upgraded to “Strong-Buy” at StockNews.com

Qiagen (NYSE:QGEN – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Friday. QGEN has been the subject of several other reports. Baird R W cut Qiagen from a “strong-buy” rating to a “hold” rating in a research note on […] - 2025-05-09 04:56:48

Zacks Research Weighs in on Qiagen’s Q3 Earnings (NYSE:QGEN)

Qiagen (NYSE:QGEN – Free Report) – Equities research analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of Qiagen in a research report issued on Thursday, April 24th. Zacks Research analyst R. Department now expects that the company will earn $0.57 per share for the quarter, down from their […] - 2025-04-29 02:54:55

LPL Financial LLC Boosts Stake in Qiagen (NYSE:QGEN)

LPL Financial LLC grew its holdings in Qiagen (NYSE:QGEN – Free Report) by 2.6% during the fourth quarter, HoldingsChannel reports. The firm owned 17,240 shares of the company’s stock after acquiring an additional 432 shares during the period. LPL Financial LLC’s holdings in Qiagen were worth $768,000 at the end of the most recent reporting […] - 2025-04-23 04:18:46

Brokerages Set Qiagen (NYSE:QGEN) Target Price at $47.71

Shares of Qiagen (NYSE:QGEN – Get Free Report) have received a consensus recommendation of “Hold” from the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month […] - 2025-04-22 02:35:00

QIAGEN Unveils QIAprep& Plasmodium Kit For Malaria Detection And Surveillance

(RTTNews) - QIAGEN N.V. (QGEN) has unveiled the QIAprep& Plasmodium Kit along with two companion assays to enhance efforts in malaria research and monitoring. This innovative solution streamlines sample preparation and quantitative PCR (qPCR) into a unified workflow, enabling fas - 2025-04-01 02:45:40

Qiagen (NYSE:QGEN) Receives $47.71 Average PT from Analysts

Shares of Qiagen (NYSE:QGEN – Get Free Report) have been assigned a consensus rating of “Hold” from the ten analysts that are presently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month target price […] - 2025-03-03 04:32:49

QIAGEN Files Patent Complaint Against BioMérieux To Protect QuantiFERON Technology

(RTTNews) - QIAGEN N.V. (QGEN) announced that it has filed a complaint against bioMrieux S.A. for patent infringement, reinforcing its commitment to protecting the scientific advancements behind its proprietary QuantiFERON technology. - 2025-03-03 04:16:07

Qiagen (NYSE:QGEN) Stock Rating Lowered by Robert W. Baird

Qiagen (NYSE:QGEN – Get Free Report) was downgraded by Robert W. Baird from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, MarketBeat reports. They currently have a $42.00 price target on the stock, down from their prior price target of $52.00. Robert W. Baird’s price […] - 2025-02-21 06:42:50

Qiagen (NYSE:QGEN) Reaches New 1-Year Low Following Analyst Downgrade

Qiagen (NYSE:QGEN – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Monday after UBS Group lowered their price target on the stock from $50.00 to $48.00. UBS Group currently has a neutral rating on the stock. Qiagen traded as low as $39.63 and last traded at $39.97, with a […] - 2025-02-12 04:14:58

Back to Listing

Disclaimer